GEHC stock news · GE HealthCare Technologies
Get alerts for GEHC
Follow GE HealthCare Technologies (GEHC) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for GEHCUBS raised its target price for GE HealthCare Technologies to $80, up from $73.
NeutralUBS raised its GE HealthCare target from $73 to $80, a 9.6% increase, but kept its Neutral rating. The update does not show a clear change in the company's outlook.
GE HealthCare Technologies Inc. announced new board members and changes in leadership roles.
NeutralGE HealthCare named Pascal Desroches to its board and committee roles; this governance change is neutral for GE HealthCare.
GE Healthcare is talking about buying Sofie Biosciences, which makes chemicals for cancer scans.
NeutralGE Healthcare is in talks to buy Sofie Biosciences for $1B. The possible deal and stalled results leave the company's picture unchanged.
GE HealthCare is close to buying Sofie Biosciences for nearly $1 billion.
Good for GEHCGE HealthCare is in talks to buy Sofie Biosciences for about $1,000,000,000, expanding its radioactive diagnostic agents business, which reads as a positive development for GEHC.
GE HealthCare Technologies Inc. details leadership transitions, including the exit and election of directors and the appointment of new officers, along with their compensation arrangements (GEHC).
NeutralGE HealthCare Technologies Inc. has filed a Form 8-K detailing significant changes in its leadership, including the departure and appointment of certain officers. Such changes can influence the company's strategic direction and operational effectiveness, which may affect investor sentiment and stock performance in the near term.
Nelson Peltz places investments on both fronts of GE's division strategy.
Good for GEHCTrian Fund Management dramatically increased its stake in GE HealthCare, suggesting strong potential for growth.